[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602942":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":19,"locations":10,"responsibleParty":28,"collaborators":10,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":36,"eligibilityCriteria":37,"healthyVolunteers":32,"sex":38,"minAge":10,"maxAge":10,"enrollmentInfo":39,"targetDuration":10,"studyType":42,"phases":10,"briefSummary":43,"conditions":44,"keywords":46,"overallStatus":52,"whyStopped":10,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":10},{"fullName":5,"class":6},"Research in Real-Life Ltd","NETWORK",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"GP practices with patients identified by one of the QIP algorithms.",null,"GP practices are the participants of the trial and not individual patients. We will invite GP practices to take part in the trial. Algorithms will be run on an anonymised dataset, OPCRD, to identify practices with high-risk patients. Practices that wish to participate and meet the trial eligibility criteria will be required to sign Clinical Trial Agreements.",[13,17],{"name":14,"affiliation":15,"role":16},"Ursie Smith, PhD MBChB MSci Bsc","Observational and Pragmatic Research Institute (OPRI)","PRINCIPAL_INVESTIGATOR",{"name":18,"affiliation":15,"role":16},"David Price, MD PhD",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Victoria Carter","CONTACT","01223967855","victoria.carter@optimumpatientcare.org",{"name":26,"role":22,"phone":23,"phoneExt":10,"email":27},"Francis Appiagyei","francis@optimumpatientcare.org",{"type":29,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100602942","channelling-algorithm-proficiency-to-understand-recognise-and-elucidate-disease-100602942",false,"NCT07130071","Channelling Algorithm Proficiency To Understand, Recognise and Elucidate Disease","A Pragmatic, Stepped Wedge, Multi-centre, Cluster Randomised Trial Evaluating the Efficiency of Algorithm Technology and Tailored Primary Care Quality Improvement Support to Identify, Diagnose and Refer Patients With Rare and Difficult to Diagnose Disease (Defined by the NHS as Those Suffering From Significant Diagnostic Odyssey)","CAPTURED","Inclusion Criteria:\n\n* General practice in the United Kingdom (England, Scotland, Wales, Northern Ireland) participating in Optimum Patient Care services and contributing deidentified data to OPCRD.\n* At least 1 patient identified as high probability of rare or difficult to diagnose disease by one of the quality improvement program algorithms.\n\nExclusion Criteria:\n\n* General practices hosting or affected by research, or other aspects of care, which might significantly influence the implementation of CAPTURED.","ALL",{"count":40,"type":41},500,"ESTIMATED","OBSERVATIONAL","Rare diseases affect over 3.5 million people in the UK. It can take years of multiple referrals, inconclusive tests or incorrect diagnoses, for patients to get a final diagnosis. We call this diagnostic odyssey, and GPs are often the first point of call for patients at the start.\n\nAlgorithms can be used to help identify patients with rare diseases faster, who may benefit from testing. They also help healthcare professionals in decision making. Healthcare providers also recognise the value of quality improvement (QI) activities, but practices are often reluctant to participate in non-QOF QI initiatives.\n\nCAPTURED aims to help reduce the diagnostic odyssey patients face by evaluating the efficiency of algorithms and tailored primary care QI support to identify, diagnose and refer patients with rare and difficult to diagnose disease. It will contribute towards these aspects of the UK Rare Disease Framework: (Priority 1) helping patients get a final diagnosis faster; and (Priority 2) increasing awareness of rare diseases among healthcare professionals.\n\nCAPTURED will run as a stepped wedge, cluster randomised trial. Practices are the participants, and not individual patients. Practices will be randomly allocated to undertake quality improvement programmes (QIP) to help evaluate up to 10 rare disease algorithms. Practices will undertake QIPs at specific times, but at the end, all practices would undertake all the QIPs they have at-risk patients for. Practices will invite at-risk patients for testing\u002Fscreening, and refer newly diagnosed patients for appropriate care. Practices will be supported with the QIPs by OPC Quality Improvement and Research Support Service, at no cost to practices.\n\nCAPTURED will run for 5 years and will enrol 500 practices. The trial does not involve any medicine, drug or equipment. The trial will use anonymised patient data collected from all participating practices into the Optimum Patient Care Research Database (OPCRD).",[45],"Rare Disorders",[47,48,49,50,51],"rare disease","rare disorder","difficult to diagnose","quality improvement","algorithm","NOT_YET_RECRUITING","2025-08-12",{"date":55,"type":56},"2025-08-19","ACTUAL",{"date":58,"type":41},"2025-10",{"date":60,"type":41},"2031-10",{"name":5,"class":6}]